Rhenman & Partners Asset Management’s Acceleron Pharma XLRN Stock Holding History

Rhenman & Partners Asset Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,392	Closed	-$756K	–	99
2021 Q3	$756K	Sell	4,392 -195,608	-98%	-$25.6M	0.05%	92
2021 Q2	$25.1M	Buy	200,000 +40,000	+25%	+$5.04M	1.7%	17
2021 Q1	$21.7M	Hold	160,000	–	–	1.51%	25
2020 Q4	$20.5M	Buy	160,000 +15,000	+10%	+$1.76M	1.67%	22
2020 Q3	$16.3M	Sell	145,000 -10,000	-6%	-$996K	1.45%	30
2020 Q2	$14.8M	Buy	155,000 +85,000	+121%	+$8.19M	1.6%	26
2020 Q1	$6.29M	Sell	70,000 -30,000	-30%	-$2.33M	0.88%	44
2019 Q4	$5.3M	Buy	100,000 +30,000	+43%	+$1.37M	0.58%	62
2019 Q3	$2.77M	Hold	70,000	–	–	0.35%	70
2019 Q2	$2.88M	Hold	70,000	–	–	0.32%	68
2019 Q1	$3.26M	Buy	+70,000	New	+$3.07M	0.38%	67

Rhenman & Partners Asset Management's XLRN Position: Q4 2021 in Review

Rhenman & Partners Asset Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 4,392 shares — an estimated $756K sold.

Rhenman & Partners Asset Management first reported a position in XLRN in Q1 2019 and held it in 11 quarters. The position peaked at $25.1M in Q2 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Rhenman & Partners Asset Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Rhenman & Partners Asset Management sold 4,392 Acceleron Pharma shares in Q4 2021, an estimated $756K.
Rhenman & Partners Asset Management first reported a position in Acceleron Pharma in Q1 2019 and held it in 11 quarters.
Rhenman & Partners Asset Management's Acceleron Pharma position peaked at $25.1M in Q2 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.